Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Outcome Of The Board Meeting

 To considered and approved the Audited Financial Results of the Company (Standalone and Consolidated) for the Quarter and Year Ended on March 31, 2020, along with the Reports of Auditors thereon. Pursuant to Regulation 33 (3) (d) of SEBI LODR Regulations, we hereby declare that the Statutory Auditors have issued Audit Report with Un-Modified Opinion on the Audited Financial Results (Standalone and Consolidated) of the Company for the Year Ended March 31, 2020. The copies of the said Declaration, Financial Results and Auditors Reports are enclosed herewith.
25-06-2020
Bigul

Annual report for Lincoln Pharmaceuticals Ltd. for FY-2020
25-06-2020
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Intimation for Audited Financial Results For The Quarter And Year Ended On March 31, 2020

 LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/06/2020 ,inter alia, to consider and approve Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Year Ended on March 31, 2020 along with any other business, if any.
15-06-2020
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosure On Material Impact Of Covid-19 (Pandemic).

 Disclosure of material impact due to Covid-19 pandemic on the the Company.
08-06-2020
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayLINCOLN PHARMACEUTICALS LTD. 2CINL24230GJ1995PLC024288 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: NIREN A DESAI Designation: COMPANY SECRETARY EmailId: cs@lincolnpharma.com Name of the Chief Financial Officer: DARSHIT A SHAH Designation: CHIEF FINANCIAL OFFICER EmailId: darshit@lincolnpharma.com Date: 30/05/2020 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
30-05-2020
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 We submit herewith the confirmation certificate received from Link Intime India Private Limited, Registrar and Share Transfer Agent (RTA) as per Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations 2018 for the Quarter Ended March 31, 2020.
30-05-2020
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliance Certificate For The Half Year Ended March 31, 2020.

 Half Yearly Compliance Certificate for the Period Ended on March 31, 2020 as required under Regulation 40 (9) of SEBI (Listing and Obligations Requirements) Regulations, 2015.
26-05-2020
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Lincoln Pharmaceuticals Limited receives European Union (EU) GMP approval.
19-05-2020
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliance Certificate For The Period Ended March 31, 2020

 Compliance Certificate Under Regulation 7 (3) of SEBI (LODR) Regulations, 2015 for the Period Ended March 31, 2020.
06-05-2020
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Statement Of Investor Complaints For The Quarter Ended March 2020

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- NIREN DESAIDesignation :- Company Secretary and Compliance Officer
30-04-2020
Next Page
Close

Let's Open Free Demat Account